Cargando…
Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells
BACKGROUND: Breast cancer (BC) cells secrete soluble factors that accelerate osteoclast (OC) differentiation, leading to the formation of osteolytic bone metastases. In the BOLERO-2 trial, BC patients with bone involvement who received Everolimus had a delayed tumor progression in the skeleton as a...
Autores principales: | Simone, Valeria, Ciavarella, Sabino, Brunetti, Oronzo, Savonarola, Annalisa, Cives, Mauro, Tucci, Marco, Opinto, Giuseppina, Maiorano, Eugenio, Silvestris, Franco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606500/ https://www.ncbi.nlm.nih.gov/pubmed/26468083 http://dx.doi.org/10.1186/s12885-015-1717-8 |
Ejemplares similares
-
Hodgkin Lymphoma: A Special Microenvironment
por: Opinto, Giuseppina, et al.
Publicado: (2021) -
Role of Bone Targeting Agents in the Prevention of Bone Metastases from Breast Cancer
por: D’Oronzo, Stella, et al.
Publicado: (2020) -
Extracellular Vesicles and Epigenetic Modifications Are Hallmarks of Melanoma Progression
por: Mannavola, Francesco, et al.
Publicado: (2019) -
Diffuse Large B Cell Lymphoma Arising in Patients with Preexisting Hodgkin Lymphoma
por: Bellitti, Emilio, et al.
Publicado: (2022) -
Osteotropism of neuroendocrine tumors: role of the CXCL12/CXCR4 pathway in promoting EMT in vitro
por: Cives, Mauro, et al.
Publicado: (2017)